Short Interest in Certara, Inc. (NASDAQ:CERT) Increases By 31.4%

Certara, Inc. (NASDAQ:CERT) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 5,360,000 shares, a growth of 31.4% from the October 15th total of 4,080,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 4.8% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $15.92.

Insider Buying and Selling

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Certara

Several institutional investors have recently modified their holdings of CERT. Blue Trust Inc. acquired a new stake in Certara during the 2nd quarter worth $26,000. Innealta Capital LLC purchased a new stake in Certara in the 2nd quarter valued at $36,000. KBC Group NV grew its position in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC acquired a new position in Certara in the 2nd quarter valued at about $152,000. Finally, Algert Global LLC purchased a new stake in Certara during the 2nd quarter valued at approximately $156,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

Shares of CERT stock traded down $0.19 during trading hours on Thursday, reaching $10.52. 617,106 shares of the company traded hands, compared to its average volume of 789,036. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a 12-month low of $9.99 and a 12-month high of $19.87. The firm has a 50-day moving average price of $10.95 and a 200 day moving average price of $13.56. The company has a market cap of $1.69 billion, a P/E ratio of -53.55, a P/E/G ratio of 5.52 and a beta of 1.51.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period last year, the company posted $0.06 earnings per share. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, sell-side analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.